Cantitate/Preț
Produs

New Approaches to Drug Discovery: Handbook of Experimental Pharmacology, cartea 232

Editat de Ulrich Nielsch, Ulrike Fuhrmann, Stefan Jaroch
en Limba Engleză Hardback – 8 apr 2016
This volume gives an overview ofstate of the art technologies and future developments in the field ofpreclinical pharmaceutical research. A balanced mix of experts from academiaand industry give insight in selected new developments in the drug discoverypathway. The topics cover the different parts of the drug discovery process,starting with new developments in the target identification and validationarea. The lead generation part as a next step focuses on the requirements andtechnologies to identify new small molecules as lead compounds for furtheroptimization; in a second section the technologies to identify biologics asleads are addressed. The final part focuses on the pharmacological models andtechnologies to characterize new compounds and the impact of biomarkers to facilitatethe transfer of drug candidates into the development phase.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 130060 lei  38-44 zile
  Springer International Publishing – 25 apr 2018 130060 lei  38-44 zile
Hardback (1) 140189 lei  3-5 săpt.
  Springer International Publishing – 8 apr 2016 140189 lei  3-5 săpt.

Din seria Handbook of Experimental Pharmacology

Preț: 140189 lei

Preț vechi: 147567 lei
-5% Nou

Puncte Express: 2103

Preț estimativ în valută:
26829 27950$ 22307£

Carte disponibilă

Livrare economică 20 ianuarie-03 februarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783319289120
ISBN-10: 3319289128
Pagini: 370
Ilustrații: VIII, 341 p. 100 illus., 63 illus. in color.
Dimensiuni: 155 x 235 x 23 mm
Greutate: 0.82 kg
Ediția:1st ed. 2016
Editura: Springer International Publishing
Colecția Springer
Seria Handbook of Experimental Pharmacology

Locul publicării:Cham, Switzerland

Public țintă

Research

Cuprins

Preface.-Part 1. Historical View.- Drug discovery in the past and today.Part 2. Target Discovery.- Emerging target families:intractable targets. In vivo target validation especially for biologicaltargets. HR RNAi/High Content analysis.- Part 3. Lead generation and Optimization.- Sources for leads: natural products,libraries. Screening: assays, readout, technology. Impact of structuralbiology, fragment based screening/Virtual screening. Predictive in silico toolsof compound properties. High throughput synthesis. New compound classes:Protein-Protein Interaction. Sources for biological leads/Screening ofbiologicals.- Part 4. Test systems forEfficacy and Safety.- In vitro/ Cell based assays. Pharmacodynamic. Pharmacokinetic. Safety and toxicology. Impactof biomarkers/personalized medicine. Simulating in vivo drug effects.

Notă biografică

Dr. Ulrich Nielsch, Bayer Pharma AG,Wuppertal, Germany
Dr. Ulrike Fuhrmann, Bayer Pharma AG, Berlin, Germany
Prof. Dr. Stefan Jaroch, Bayer Pharma AG, Berlin, Germany

Caracteristici

In depth insights into drug discovery and early drug development Latest technologies of target discovery and lead generation New approaches to transfer drug candidates to clinical development